DANAHER CORP DE（DHR）の決算・業績分析
DANAHER CORP DEの2025年有価証券報告書をAI分析。売上高$24.6B(+2.9%)。営業利益$4.7B。Health Care。
目次
DANAHER CORP DEの2025年度 業績サマリー
DANAHER CORP DE（証券コード: DHR）の2025年度決算・業績分析。売上高は$24.6B（前年比+2.9%）。営業利益は$4.7B（前年比-3.6%）。純利益は$3.6B（前年比-7.3%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
DANAHER CORP DEの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 7.4% YoY to $26.6B (XBRL), driven by strong performance in biotechnology and diagnostics.
- Operating income surged 18.2% YoY to $7.5B (XBRL), with gross margin at 60.8% (XBRL) and net margin at 27.1% (XBRL).
- Free cash flow (FCF) reached $7.4B (XBRL), reflecting disciplined capital allocation and $1.1B (XBRL) in CapEx.
DANAHER CORP DEの売上高変化の要因
- •Revenue increased 7.4% YoY to $26.6B (XBRL), with a 5-year CAGR of 7.0% (XBRL). Operating income grew 18.2% YoY to $7.5B (XBRL), reflecting a 5-year CAGR of 11.2% (XBRL). Net income rose 12.1% YoY to $7.2B (XBRL), with a 5-year CAGR of 12.4% (XBRL). Historical time series data shows consistent growth in revenue and operating income, though FY2025 revenue declined to $23.9B (XBRL).
DANAHER CORP DEの営業利益変化の要因
- •Gross margin remained robust at 60.8% (XBRL), while operating margin expanded to 28.3% (XBRL) and net margin reached 27.1% (XBRL). Operating income grew 18.2% YoY (from $6.4B in FY2023 to $7.5B in FY2024) (XBRL), and net income increased 12.1% YoY (from $6.4B to $7.2B) (XBRL). EBITDA of $8.2B (XBRL) represents a 30.9% margin (XBRL).
DANAHER CORP DEの事業リスクと対応
Global economic conditions (e.g., inflation, interest rates, geopolitical events) could reduce demand, increase costs, and disrupt operations (10-K).
Intense competition may force price reductions and erode market share (10-K).
Supply chain disruptions or cost increases could harm production and profitability (10-K).
Regulatory changes, trade policies, or geopolitical tensions may impact operations and markets (10-K).
Impairment of goodwill or long-lived assets due to economic downturns or market shifts (10-K).
DANAHER CORP DEの事業内容
Danaher Corp operates as a global science and technology innovator, generating revenue through the sale of products and services in biotechnology, life sciences, and diagnostics (10-K). Its business model relies on recurring sales via a direct sales model to a geographically diverse customer base (10-K). Key segments include Biotechnology (bioprocessing, discovery, and medical businesses), Life Sciences, and Diagnostics (10-K). Danaher's competitive advantage stems from its DANAHER BUSINESS SYSTEM (DBS), which drives operational efficiency and innovation (10-K). Strategic acquisitions and R&D investments ($1.5B in 2024) (XBRL) reinforce its market position.
DANAHER CORP DEのAI業績分析レポート（2024年度）
Danaher Corp (DHR) FY2024 Annual Report Analysis
Highlights
Business Overview
Danaher Corp operates as a global science and technology innovator, generating revenue through the sale of products and services in biotechnology, life sciences, and diagnostics (10-K). Its business model relies on recurring sales via a direct sales model to a geographically diverse customer base (10-K). Key segments include Biotechnology (bioprocessing, discovery, and medical businesses), Life Sciences, and Diagnostics (10-K). Danaher's competitive advantage stems from its DANAHER BUSINESS SYSTEM (DBS), which drives operational efficiency and innovation (10-K). Strategic acquisitions and R&D investments ($1.5B in 2024) (XBRL) reinforce its market position.
Revenue Analysis
Revenue increased 7.4% YoY to $26.6B (XBRL), with a 5-year CAGR of 7.0% (XBRL). Operating income grew 18.2% YoY to $7.5B (XBRL), reflecting a 5-year CAGR of 11.2% (XBRL). Net income rose 12.1% YoY to $7.2B (XBRL), with a 5-year CAGR of 12.4% (XBRL). Historical time series data shows consistent growth in revenue and operating income, though FY2025 revenue declined to $23.9B (XBRL).
Profitability Analysis
Gross margin remained robust at 60.8% (XBRL), while operating margin expanded to 28.3% (XBRL) and net margin reached 27.1% (XBRL). Operating income grew 18.2% YoY (from $6.4B in FY2023 to $7.5B in FY2024) (XBRL), and net income increased 12.1% YoY (from $6.4B to $7.2B) (XBRL). EBITDA of $8.2B (XBRL) represents a 30.9% margin (XBRL).
Balance Sheet Analysis
Equity ratio stood at 63.4% (XBRL), with total assets of $84.3B (XBRL) and total equity of $53.5B (XBRL). Current ratio was 1.68x (XBRL), indicating strong liquidity. ROE was 13.5% (XBRL) and ROA was 8.6% (XBRL). Long-term debt totaled $16.7B (XBRL).
Cash Flow Analysis
Operating cash flow reached $8.5B (XBRL), with FCF of $7.4B (XBRL) after $1.1B (XBRL) in CapEx. Investing cash flow was -$2.2B (XBRL), and financing cash flow was -$2.6B (XBRL), driven by $818M (XBRL) in dividends paid and no share repurchases (XBRL). CapEx intensity was 4.2% (XBRL), with a CapEx/D&A ratio of 1.60x (XBRL).
Working Capital Analysis
Receivables Days: 54 days (XBRL); Inventory Days: 91 days (XBRL). Payables Days: N/A. Cash Conversion Cycle (CCC): N/A (insufficient data).
Risks
Outlook
N/A (management guidance and forward-looking trends are not explicitly mentioned in the 10-K).
Health Careの企業一覧
DANAHER CORP DEと同じ「Health Care」セクターの企業